-
Abstract Number: 524
A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies
-
Abstract Number: 525
Factors Associated with Persistent Drug-free Remission in Patients with Rheumatoid Arthritis
-
Abstract Number: 526
Factors Influencing Discontinuation in Long-term RA Treatment
-
Abstract Number: 527
Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks
-
Abstract Number: 528
Assessment of Bone and Cartilage Turnover Markers Following Treatment with Repository Corticotropin Injection in Patients with Persistently Active Rheumatoid Arthritis
-
Abstract Number: 529
Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators
-
Abstract Number: 530
Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay
-
Abstract Number: 531
Efficacy and Safety of Gonadotropin-Releasing Hormone Antagonism in Severe Biologic Refractory Rheumatoid Arthritis
-
Abstract Number: 532
A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, ㏌ Patients with Rheumatoid Arthritis Inadequately Responding to Biologics
-
Abstract Number: 533
Impact of Formulary Change on TNFi Treatment Patterns and Healthcare Utilization Costs in RA Patients
-
Abstract Number: 534
CXCL13 Serum Levels and Circulating Follicular Helper T-Cells Decrease After Co-stimulation Blockade with Abatacept in Rheumatoid Arthritis
-
Abstract Number: 535
Exploratory Analysis of a Phase 2b Study Confirms Substantial Pain Improvement with Anti-GM-CSF Monoclonal Antibody Otilimab (GSK3196165) in Patients (Pts) with Active RA
-
Abstract Number: 536
PERFUSE: A French Prospective/Retrospective Non-interventional Cohort Study of Infliximab-naïve and Transitioned Patients Receiving Infliximab Biosimilar SB2; An Interim Analysis
-
Abstract Number: 537
Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA
-
Abstract Number: 538
Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks
- « Previous Page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- …
- 198
- Next Page »